Price CAGR:-12.16%(TTM)
Over the latest trailing 12-month period, price cagr is -12.16%. The comparable SPY value is +19.16%. Year-to-date price return is -20.60%. Price CAGR uses adjusted close price history and excludes dividends.
Over longer horizons, Price CAGR averages -5.45% over 3 years. The price CAGR (Compound Annual Growth Rate) shows how the company's stock price has grown over various time periods. This measures pure price appreciation without including dividends.
GEHC Price CAGR Chart
GE HealthCare Technologies Inc. (GEHC)
GEHC Quarterly Price (YoY)
Price growth vs the same quarter one year earlier, last 11 quarters.
GEHC Price CAGR History
| Year | Start Price | End Price | Change | % Change | CAGR |
|---|---|---|---|---|---|
| 2025 | 77.09 | 83.94 | +6.85 | +8.89% | +8.89% |
| 2024 | 75.06 | 77.09 | +2.03 | +2.70% | +2.70% |
| 2023 | 60.00 | 75.06 | +15.06 | +25.10% | +25.10% |
Quarterly Price: QoQ & YoY
| Quarter | Value | QoQ | YoY |
|---|---|---|---|
| Q2 2026 | 66 | -7.6% | -11.2% |
| Q1 2026 | 71 | -13.2% | -11.8% |
| Q4 2025 | 82 | +9.2% | +4.9% |
| Q3 2025 | 75 | +1.4% | -20.0% |
| Q2 2025 | 74 | -8.2% | -4.9% |
| Q1 2025 | 81 | +3.2% | -11.2% |
| Q4 2024 | 78 | -16.7% | +1.1% |
| Q3 2024 | 94 | +20.4% | +37.9% |
| Q2 2024 | 78 | -14.3% | -4.1% |
| Q1 2024 | 91 | +17.6% | +10.8% |
| Q4 2023 | 77 | +13.6% | +32.4% |
| Q3 2023 | 68 | -16.2% | — |
| Q2 2023 | 81 | -1.0% | — |
| Q1 2023 | 82 | +40.5% | — |
| Q4 2022 | 58 | — | — |
QoQ = change vs the prior quarter; YoY = change vs the same quarter a year earlier.
About GE HealthCare Technologies Inc.
GE HealthCare Technologies Inc. is a global medical technology company that creates, manufactures, and markets a diverse range of medical devices, services, and integrated digital solutions. These offerings are designed to assist in the diagnosis, treatment, and ongoing monitoring of patients. The company boasts an extensive international presence, serving markets across the United States, Canada, Europe, the Middle East, Africa, China, Taiwan, Mongolia, and Hong Kong, among other regions. Its operations are structured across four primary business divisions: Imaging, Ultrasound, Patient Care Solutions, and Pharmaceutical Diagnostics. The Imaging division specializes in advanced diagnostic imaging technologies, including systems for molecular imaging, Computed Tomography (CT) scans, Magnetic Resonance (MR) imaging, image-guided therapy, and X-ray, alongside specialized women's health products. The Ultrasound segment delivers a comprehensive suite of ultrasound solutions utilized for the screening, diagnosis, treatment, and monitoring of various diseases. These applications span radiology, primary care, women's health, cardiovascular diagnostics, point-of-care, and portable handheld devices, in addition to products supporting surgical visualization and guidance. The Patient Care Solutions segment is dedicated to providing essential medical devices, consumable products, services, and digital platforms. Its portfolio encompasses patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, and maternal-infant care products. The Pharmaceutical Diagnostics segment supplies specialized diagnostic agents to the radiology and nuclear medicine industries. These include contrast media pharmaceuticals, administered to patients prior to scans like CT, angiography, X-ray, and MR, to enhance the visibility of internal tissues and structures. It also offers molecular imaging agents, or radiopharmaceuticals – molecular tracers labeled with radioisotopes – injected into patients for advanced diagnostic imaging applications such as Single-Photon Emission Computed Tomography (SPECT), Positron Emission Tomography (PET), and specific ultrasound procedures. Established in 2022, GE HealthCare Technologies Inc. maintains its corporate headquarters in Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- CEO
- Peter J. Arduini